Figures & data
Figure 1. Definition of bleeding episodes used for the descriptive analysis.
Table 1. Baseline characteristics of participants in the phase II and III studies.
Figure 2. Proportion of women experiencing (A) bleeding and/or spotting days per month; (B) bleeding days per month; (C) spotting days per month. (Pooled data, 30-day reference period, n = 1697).
Figure 3. Median number of bleeding and/or spotting days per month (30-day reference period) according to previous contraceptive method (n = 1452).
Table 2. Proportion of participants experiencing bleeding and/or spotting days per month, categorised by previous contraceptive use.
Table 3. Median number of bleeding and/or spotting days per month, by age group.
Table 4. Median percentage of bleeding days within overall number of bleeding and/or spotting days per month.
Figure 4. Proportion of women experiencing bleeding/spotting days per 360-day reference period (n = 1452).
Figure 5. In reference period 1, total women using 13.5 mg LNG-IUS = 231, 19.5 mg LNG-IUS = 242, and 52 mg LNG-IUS = 250; In reference period 2, total women using 13.5 mg LNG-IUS = 229, 19.5 mg LNG-IUS = 241, and 52 mg LNG-IUS = 247; In reference period 3, total women using 13.5 mg LNG-IUS = 228, 19.5 mg LNG-IUS = 240, and 52 mg LNG-IUS = 245; In reference period 12, total women using 13.5 mg LNG-IUS = 216, 19.5 mg LNG-IUS = 216, and 52 mg LNG-IUS = 223.
